Cohance Lifesciences Share Price: Profit mein laga bada jhatka! Share girne ka reason aur future outlook.

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Cohance Lifesciences Share Price: Profit mein laga bada jhatka! Share girne ka reason aur future outlook.
Overview

Cohance Lifesciences ke investors ke liye aaj khabar achhi nahi hai. Company ne Q4 mein profit mein **84%** ki zabardast girawat dikhai hai, jo **₹120.4 Crore** se ghat kar sirf **₹20 Crore** reh gaya hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Q4 Results: Profit aur Revenue dono down!

Asal mein, company ka Net Profit 84% gir kar sirf ₹20 Crore reh gaya hai, jo pichhle saal isi quarter mein ₹120.4 Crore tha. Revenue bhi 26.3% neeche aaya hai, ab ₹619.1 Crore ho gaya hai.

EBITDA aur Margins par bhi pressure

Sirf profit hi nahi, EBITDA bhi 60% ho gaya kam, matlab ₹98.7 Crore pe aa gaya, jo pehle ₹229.2 Crore tha. Iski wajah se company ke operating margins bhi kaafi tight ho gaye hain, 15.9% pe aa gaye hain jo pehle 27.3% the.

Aage kya? FY27 mein recovery ki umeed

Ab sawaal aata hai ki aage kya? Company ka kehna hai ki FY27 ke second half mein growth phir se start ho sakti hai. Unhone saaf bola hai ki FY27 ka pehla quarter sabse mushkil rahega, revenue aur EBITDA dono ke liye.

Recovery drivers aur strong pipeline

Yeh recovery kahan se aayegi? Company ko apne current projects, naye customers aur manufacturing platforms ke better use se umeed hai. Aur haan, in sab challenges ke beech bhi, unka pipeline kaafi solid dikh raha hai. Small molecules, ADCs, aur complex chemistries ke liye proposals aa rahe hain. Ab bas bade projects mein win rates improve karne par focus hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.